Clinical Trial Update
DRY AMD► Study: Clinical Study to Investigate Safety and Efficacy of GSK933776 in Adult Patients With Geographic Atrophy Secondary to Age-related Macular DegenerationSponsor: GlaxoSmithKline Purpose: To determine the safety and efficacy of GSK933776 in the treatment of geographic atrophy secondary to age-related macular degeneration Design:Interventional, Randomized, Safety/Efficacy, Parallel Assignment, Double-blind, Treatment Number of Patients: 162 Inclusion Criteria: Evidence of AMD confirmed by the presence of at least 1 druse ≥ 125µm diameter; well-demarcated GA due to AMD of total area 1.9-17 mm2 measured in the study eye; best-corrected visual acuity score of ≥ 55 letters (approximately 20/80 Snellen VA equivalent or better) in the study eye Exclusion Criteria: Additional eye disease in the study eye that could compromise assessment of best-corrected visual acuity or imaging of the posterior pole; history of CNV in either eye; any previous treatment for AMD approved or investigational, with the exception of dietary supplements Information: GSKClinicalSupportHD@gsk.com ► Study: Safety and Tolerability of Sub-retinal Transplantation of hESC-derived RPE (MA09-hRPE) Cells in Patients With Advanced Dry Age Related Macular Degeneration Sponsor: Advanced Cell Technology Purpose:To evaluate the effect of subretinal injection of human embryonic stem cell-derived retinal pigment epithelium cells in patients with dry age-related macular degeneration(AMD) and to perform exploratory evaluation of potential efficacy endpoints to be used in future studies of retinal pigment epithelium(RPE) cellular therapy Design: Interventional, Safety, Single-group Assignment, Open Label Number of Patients: 12 Inclusion Criteria: Clinical findings consistent with advanced dry AMD with evidence of one or more areas of >250microns of geographic atrophy (as defined in the Age-Related Eye Disease Study [AREDS] study) involving the central fovea; GA defined as attenuation or loss of RPE as observed by biomicroscopy, OCT, and FA; no evidence of current or prior choroidal neovascularization Exclusion Criteria: Presence of active or inactive CNV; presence or history of retinal dystrophy, retinitis pigmentosa, chorioretinitis, central serious choroidopathy, diabetic retinopathy or other retinal vascular or degenerative disease other than AMD; history of optic neuropathy Information: schwartz@jsei.ucla.edu ► Study: A Study of Safety, Tolerability, and Evidence of Activity of FCFD4514S Administered Monthly or Every Other Month to Patients With Geographic Atrophy Sponsor: Genentech Purpose: To evaluate the safety, tolerability, and evidence of activity of FCFD4514S intravitreal injections administered monthly or every other month in patients with geographic atrophy Design: Randomized, Parallel Assignment, Single-blind, Treatment Design: Randomized, Parallel Assignment, Single-blind, Treatment Number of Patients: 120 Inclusion Criteria: Well-demarcated area of GA secondary to age-related macular degeneration (AMD) in the absence of choroidal neovascularization (CNV) Exclusion Criteria: History of vitrectomy surgery, submacular surgery, or other surgical intervention for AMD in the study eye; previous subfoveal focal laser photocoagulation in the study eye; laser photocoagulation in the study eye; prior treatment with Visudyne, external-beam radiation therapy, or transpupillary thermotherapy in the study eye Information: sullivan.amy@gene.com ► Study: A Study of the Safety and Efficacy of CNTO2476 in Patients With Agerelated Macular Degeneration Sponsor: Centocor, Inc. Purpose: To assess the effects (good and bad) of a therapy called CNTO 2476 for patients with age-related macular degeneration Design: Interventional, Randomized, Safety/Efficacy, Single-group Assignment, Open Label, Treatment Number of Patients: Not given Inclusion Criteria: Patient is a suitable candidate for ophthalmologic surgery, is willing and able to comply with the surgical procedure, scheduled visits, treatment plan, laboratory tests and other study procedures; confirmed diagnosis of bilateral geographic atrophy (GA) of the macula bilaterally caused by age-related macular degeneration Exclusion Criteria: Evidence of other significant ophthalmologic disease; ocular hypertension; previous cell therapy other than blood components Information: info1@veritasmedicine.com ► Study: COMPLETE: Complement Inhibition With Eculizumab for the Treatment of Non-Exudative Macular Degeneration Sponsor: University of Miami/Alexion Pharmaceuticals Purpose: To evaluate the safety and efficacy of eculizumab for the treatment of dry AMD as evaluated by the change in drusen volume and area of geographic atrophy. Design: Treatment, Randomized, Double-blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Safety/Efficacy Study Number of Patients: 60 Inclusion Criteria: In the study eye(s), the presence of non-exudative AMD documented by fundus photography, autofluorescence, fluorescein angiography, and spectral domain OCT; visual acuity of 20/63 Exclusion Criteria: Visual acuity worse than 20/63; any history of choroidal neovascularization in the study eye; unresolved meningococcal disease; confounding ocular conditions such as amblyopia; aphakia; myopia requiring >6 D of correction Information: (305) 326-6148 ► Study: TORPA: Toronto and Oak Ridge Photobiomodulation Study for Dry Age-Related Macular Degeneration Sponsor: Graham Merry, MD Information: (865) 483-6399 ► Study: A Multi-Center Study of Reading Rehabilitation in Macular Disease Sponsor: Department of Veterans Affairs Information: pdgrant@uic.edu ► Study: Fluocinolone Acentonide Intravitreal Inserts in Geographic Atrophy Sponsor: Alimera Sciences Information: lschulz@med.wayne.edu ► Study: Safety Study in Retinal Transplantation for Dry Age-Related Macular Degeneration Sponsor: Ocular Transplantation; National Neurovision Research Institute Information: nradtke@rvrc.com |
WET AMD► Study: Home Vision Monitoring Using the ForeseeHome Device Following Treatment of Neovascular Age Related Macular DegenerationSponsor: Notal Vision, Ltd. Purpose: To evaluate if, in post-treatment patients, PHP parameters as measured with the ForeseeHome are in agreement with clinical decisions and retinal characteristics as measured with optical coherence tomography Design: Observational, Cohort, Prospective Number of Patients: 120 Inclusion Criteria: Received intravitreal antiangiogenic therapy for CNV in the study eye (SE), within 2-12 months prior to the study; last diagnosis was, and current diagnosis is, no CNV activity in SE eye; current plan in SE is clinical examination as standard care but at intervals of not more than 8 weeks Exclusion Criteria: Evidence of macular disease other than AMD or glaucoma in SE; presence of any significant media opacity that precludes a clear view of the macular area as identified in SE by biomicroscopy; any nonmacular related ocular surgery performed within 3 months prior to study entry in SE Information: (410) 686-3000 ► Study: 12 Week Patient Study in Neovascular Age-related Macular Degeneration Sponsor: GlaxoSmithKline Purpose: To investigate the safety and efficacy of a single dose regimen of pazopanib eye drop for neovascular AMD Design: Efficacy, Single-group Assignment, Open Label, Treatment Number of Subjects: 27 Inclusion Criteria: For each subject enrolled in the study, only one eye (study eye) will be treated, and eligibility criteria apply to the study eye. All of the following characteristics are required and must be confirmed by the central reading center: CNV caused by AMD that extends under the geometric center of the foveal avascular zone; center subfield thickness (inclusive of subretinal fluid) > 320 microns on OCT Exclusion Criteria: Additional eye disease in the study eye that could compromise bestcorrected visual acuity (eg, glaucoma with documented visual field loss, clinically significant diabetic retinopathy, ischemic optic neuropathy, infection or retinitis pigmentosa); CNV in the study eye due to other causes unrelated to age-related macular degeneration; presence of retinal angiomatous proliferation (RAP) in the study eye, as determined by the investigator (confirmation by indocyanine green angiography is not required) Information: GSKClinicalSupportHD@gsk.com ► Study: Evaluation of AL-78898A in Exudative Age-Related Macular Degeneration Sponsor: Alcon Research Purpose: To assess whether AL-78898A, 5.25 mg is able to delay the need for reinjection in patients with exudative AMD Design: Interventional, Randomized, Parallel Assignment, Double-blind, Treatment Number of Patients: 110 Inclusion Criteria: Presence of active juxta-or subfoveal choroidal neovascularization secondary to AMD; central subfield macular thickness of >315 ·m as assessed by SD-OCT; diagnosis of AMD within the previous 12 months with no fewer than 3 and no more than 12 Lucentis® or Avastin® treatments Exclusion Criteria: History or current evidence of macular or retinal disease in the study eye other than exudative AMD; any evidence of fibrosis or scarring within the CNV lesion in the study eye; any evidence of vitreous hemorrhage in the study eye Information: (888) 451-3937 ► Study: COMPASS: Clinical Assessment Of Age-related Macular Degeneration Patients After Early Diagnosis and Treatment With Ranibizumab Sponsor: University of California, San Diego/Genentech Purpose: To determine if patients treated early after diagnosis of wet age-related macular degeneration can return/maintain to their baseline pre-disease BCVA Design: Intervention, Safety/Efficacy, Singlegroup Assignment, Open Label, Treatment Number of Patients: 40 Inclusion Criteria: Naïve wet-AMD within 4 months of disease onset (for GALLEY patients) and within 3 months of disease onset for all others; patients that have lost > 5 letters from baseline best vision; BCVA 20/25-20/320 Exclusion Criteria: Any other condition that the investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated; participation in another simultaneous medical investigation or trial which includes an intervention (Patients could be participating in a non-interventional study such as the GALLEY study); juxtafoveal and extrafoveal wet-AMD Information: CJL015@ucsd.edu ► Study: ESBA1008 Safety, Tolerability and Effects in Wet Age-related Macular Degeneration (AMD) Patients Sponsor: Alcon Research Purpose: To evaluate the safety, tolerability and effects of an investigational drug ESBA1008 for the treatment of exudative agerelated macular degeneration Design: Interventional, Randomized, Parallel Assignment, Double-blind, Treatment Number of Patients: 90 Inclusion Criteria: Primary subfoveal choroidal neovascularization (CNV) secondary to AMD, including predominantly classic, minimally classic or occult lesions in study eye; a new diagnosis of exudative AMD or evidence of recent disease progression within the last 3 months in study eye Exclusion Criteria: Study eye must not have been treated for wet AMD previously; study eye must not have any other ocular disease, condition, infection or recent surgery that would interfere with vision or examination of the back of the eye; study eye must not have uncontrolled glaucoma and/or must not be missing a lens Information: (888) 451-3937 ► Study: Study of Dark Adaptation in Age-Related Macular Degeneration Sponsor: National Eye Institute Purpose: To evaluate the effectiveness of using a dark adaptation protocol to identify and monitor early to middle dry age-related macular degeneration Design: Observational, Prospective Number of Patients: 200 Inclusion Criteria: Group 0: Participant without AMD defined as no large drusen or advanced AMD in either eye; Group 1: Participant has at least one large drusen (greater than or equal to 125 microns) in the study eye and no large drusen or advanced AMD in the fellow eye; Group 2: Participant has bilateral large drusen (greater than or equal to 125 microns) with or without retinal pigment epithelial hypo/hyperpigmentary changes; Group 3: Participant has at least one large drusen (greater than or equal to 125 microns) in the study eye and advanced AMD in the fellow eye Exclusion Criteria: Participant has advanced AMD (as defined in Appendix 1) in the study eye at the baseline visit; participant has other active ocular or macular diseases (eg, diabetic macular edema, retinal vein occlusion, Stargardt's disease or cone-rod dystrophy) or other known ocular disorders that have caused a visual field deficit (eg, glaucoma with known visual field defect) in the study eye Information: prpl@mail.cc.nih.gov ► Study: CFH&AMD: Complement Factor H Haplotypes and Smoking in Age-related Macular Degeneration Sponsor: Department of Veterans Affairs Purpose: To the hypothesis that smoking increases age-related macular degeneration (AMD) by increasing complement activation; and that this is positively correlated with known disease variations in the complement factor H (CFH) gene Design: Observational, Cohort, Prospective Number of Patients: 300 Inclusion Criteria: Inclusion criteria for subjects will be a clear diagnosis of age-related macular degeneration (AMD) Exclusion Criteria: We will exclude individuals with ocular diseases that might simulate age-related macular degeneration (AMD) or preclude its diagnosis Information: rohrer@musc.edu ► Study: Tools to Optimize Patient Presentation After Onset of Exudative Age-Related Macular Degeneration Sponsor: Johns Hopkins University Purpose: To demonstrate that use of the test booklet leads to more rapid identification of newly developing vision problems, earlier diagnosis and treatment of incipient wet AMD that should result in fewer people losing their vision and less severe losses of vision Design: Interventional, Randomized, Safety/Efficacy, Parallel Assignment, Open Label, Diagnostic Number of Patients: 1000 Inclusion Criteria: Subjects with a confirmed diagnosis of AREDS grade 3 or 4 AMD in at least one eye will be recruited for components 1 and 2 of the study Exclusion Criteria: Subjects with vision loss due to ocular pathology other than AMD or cataracts will be excluded Information: gdagnelie@jhmi.edu ► Study: iSONEP to Treat Persistent Pigment Epithelial Detachment (PED) in Subjects With Exudative Age-Related Macular Degeneration (AMD) or Polypoidal Choroidal Vasculopathy (PCV) Sponsor: Lpath/Pfizer Purpose: To evaluate the safety and potential efficacy of iSONEP following one, two or three injections of iSONEP, as needed, for the treatment of Pigment Epithelial Detach ment (PED) secondary to PED Secondary to Exudative Age-Related Macular Degenera tion (AMD) or Polypoidal Choroidal Vascu lopathy (PCV) Design: Randomized, Safety/Efficacy, Interventional, Single-group Assignment, Open Label, Treatment Number of Patients: 32 Inclusion Criteria: Serous and/or fibro vascular PED secondary to exudative AMD or secondary to PCV (confirmed by SDOCT, FA and ICG) that has not demonstrated at least a 25% decrease in the height of the PED (from the onset of anti-VEGF therapy) following a minimum of 3 doses of an anti-VEGF agent Exclusion Criteria: Subjects previously treated with, or are currently receiving treatment with another investigational agent or device for neovascular AMD in the study eye Information: jada@crmd.net ► Study: Safety and Preliminary Efficacy Study of WST11 (Stakel®)-Mediated VTP Therapy in Subjects With CNV Associated With AMD Sponsor: Steba Biotech S.A. Purpose: To evaluate the safety (first objective) and efficacy (second objective) of an experimental drug product, Stakel®, in the treatment of neovascular AMD. The drug product is activated in patients by exposure to light at a specific wavelength ("Vascular Targeted Photodynamic therapy," "VTP") Design: Interventional, Safety/Efficacy, Singlegroup, Open Label, Treatment Number of Patients: 18 Inclusion Criteria: Twenty eight days or more after at least one ranibizumab injection, recurrent leakage on FA from subfoveal CNV (ie, CNV previously diagnosed and treated with antivascular endothelial growth factor (VEGF) therapy resulting in resolution of leakage or optical coherence tomography (OCT) thickening but currently presenting with new fluorescein leakage from CNV associated with OCT thickening) secondary to AMD Exclusion Criteria: Permanent structural damage to the center of the fovea of the study eye, or a concurrent ocular or systemic condition that could contraindicate admin istration of an investigational drug, Stakel® Solution, or fluorescein, affect interpretation of study results, or render the subject at a high risk of treatment complications Information: ascott28@jhmi.edu ► Study: GEM: Phase I Dose Escalation Safety Study of RetinoStat in Advanced Age-Related Macular Degeneration (AMD) Sponsor: Oxford BioMedica Purpose: To examine the safety of an experimental gene transfer agent, RetinoStat, designed to treat neovascular age-related macular degeneration Design: Interventional, Safety, Single-group Assignment, Open Label, Treatment Number of Patients: 18 Inclusion Criteria: Clinical diagnosis of AMD with active CNV that shows evidence of leakage; BCVA less than or equal to 20/200 in the study eye Exclusion Criteria: Significant ocular abnormalities that prevent retinal assessment; treatment with steroids within three months of screening; treatment with anti-VEGF therapy to either eye within one month of screening Information: pcampo@jhmi.edu ► Study: Intravitreal LFG316 in Patients With Advanced Age-related Macular Degeneration Sponsor: Novartis Purpose: To assess the safety, tolerability, and serum pharmacokinetics of intravitreal LFG316 in patients with advanced age-related macular degeneration Design: Interventional, Nonrandomized, Parallel Assignment, Open Label, Treatment Number of Patients: 30 Inclusion Criteria: Male or female AMD patients 55 to 90 years old, inclusive; in either eye, diagnosis of geographic atrophy or choroidal neovascularization due to AMD Exclusion Criteria: Retinal disease other than AMD in study eye which, in the investigator's opinion, may pose a safety risk or interfere with the study; choroidal neovascularization due to a cause other than AMD Information: jminer@retinalconsultantsaz.com ► Study: Serial Retinal Thickness Changes And Scotoma Size Measured With Lucentis Therapy (FVF4193s) Sponsor: New York Eye & Ear Infirmary/Genentech Purpose: To accurately measure anatomic response to treatments thereby enhancing the ability to understand patterns of response and predict the necessity for continued therapy Design: Interventional, Active Control, Safety/Efficacy, Single Group, Open Label, Treatment Number of Patients: 20 Inclusion Criteria: Best-corrected visual acuity in the study eye between 20/40 and 20/320; subfoveal choroidal neovascularization Exclusion Criteria: Had ocular surgery within the past 60 days in the study eye; had previous refractive eye surgery (RK, PRK, LASIK, ALK, etc.) within the past 3 months for the study eye; has intraocular pressure >25 mm Hg in the study eye Information: ktai@nyee.edu ► Study: Prospective Randomized Trial of Proton Beam Combined With Anti-VEGF Therapy for Exudative Agerelated Macular Degeneration Sponsor: University of California, Davis Purpose: To test the hypothesis that proton beam irradiation combined with intravitreal anti-VEGF therapy is safe and potentially more effective than intravitreal anti-VEGF therapy alone in eyes with exudative AMD Design: Randomized, Placebo Control, Safety/Efficacy, Parallel Assignment, Doubleblind, Treatment Number of Patients: 45 Inclusion Criteria: Visual acuity 20/40 to 20/400; lesion size < 12 Disc Area; submacular hemorrhage less than 75% of total lesion and not involving foveal center; submacular fibrosis less than 25% of total lesion Exclusion Criteria: Previous treatment with Photodynamic Therapy (PDT) or thermal laser in study eye; anti-VEGF therapy within 6 weeks; intravitreal or subtenon's Kenalog within 6 months Information: (916) 734-6074 ► Study: HiPED: High-Dose Lucentis for Persistent Pigment Epithelial Detachments in Age-related Macular Degeneration Sponsor: Pacific Eye Associates/Genentech Purpose: To evaluate the efficacy and safety of 2 mg ranibizumab, specifically for patients with fibrovascular PEDs that have not resolved following at least 6 consecutive injections of ranibizumabor bevacizumab over the previous 12 months Design: Interventional, Randomized, Dose Comparison, Safety/Efficacy, Parallel Assignment, Open Label, Treatment Number of Patients: 40 Inclusion Criteria: Active or recurrent neovascular age-related macular degeneration involving the fovea on FA; presence of persistent fibrovascular pigment epithelial detachment on OCT following a minimum of 6 previous treatments in previous 12 months with ranibizumab and/or bevacizumab Exclusion Criteria: Prior treatment with verteporfin, or external-beam radiation therapy, or transpupillary thermotherapy; previous sub-foveal focal laser photocoag ulation involving the foveal center Information: pearesearch@yahoo.com ► Study: Phase I Study of Palomid 529, a Dual TORC1/2 Inhibitor of the PI3K/Akt/m TOR Pathway for Advanced Neovascular AMD (P52901) Sponsor: Paloma Pharmaceuticals, Inc. Purpose:To determine if the safety, tolerability and pharmacokinetic profile of single ascending doses when administered intravitreally or subconjunctivally Design: Interventional, Uncontrolled, Safety/Efficacy, Single-group Assignment, Open Label, Treatment Number of Patients: 33 Inclusion Criteria: Best-corrected visual acuity in the study eye between 20/100 and 20/800 (between 53 and 4 ETDRS letters read), and better or equal to 20/200 (minimum of 34 letters read) in the fellow eye Exclusion Criteria: Any retinovascular disease or retinal degeneration other than AMD; serous pigment epithelial detachment without the presence of neovascularization; previous posterior vitrectomy or retinal surgery Information: anowak@eyeboston.com ► Study: IBI 20089+Lucentis Combo Intravitreal Injections for Treatment of Neovascular AMD (Icon Combo) Sponsor: Univ. of Illinois/Icon Bioscience, Inc. Purpose: To assess the safety and tolerability of an investigational drug called IBI-20089 (6.9 mg and 13.8 mg) when used adjunctively with Lucentis 0.5 mg in subjects with subfoveal neovascular AMD Design: Interventional, Safety/Efficacy, Singlegroup Assignment, Open Label, Treatment Number of Patients: 5 Inclusion Criteria: Diagnosis of active, subfoveal choroidal neovascular membranes due to agerelated macular degeneration; visual acuity from 20/50 to 20/400 in the study eye Exclusion Criteria: Subjects who have received corticosteroids via any route in the past 90 days; in the opinion of the investigator, patient at risk of elevated ocular pressure or is known to be a steroid-responder Information: alcmalek@uic.edu ► Study: Dose Ranging Study of Pazopanib to Treat Neovascular AMD Sponsor: GlaxoSmithKline Purpose: To determine the safety and efficacy of different dosage regimens of pazopanib eye drops for the treatment of neovascular age-related macular degeneration Design: Randomized, Safety/Efficacy Study, Parallel Assignment, Double-blind, Treatment Number of Patients: 630 Inclusion Criteria: Active subfoveal CNV lesion secondary to AMD in study eye: Total lesion area ≤12 disc areas with CNV ≥50% total lesion area; anti-VEGF intravitreal injection experienced and in need of re-treatment Exclusion Criteria: Prior ocular investigational drug/device for choroidal neovascularization, photodynamic therapy, radiation, subfoveal or juxtafoveal focal laser photocoagulation; prior failure to anti-VEGF intravitreal injection therapy Information: (877) 379-3718 ► Study: LAST: A Pilot Study to evaLuate the Role of High-dose rAnibizumab (2.0mg) in the Management of AMD in Patients With perSistent/recurrenT Macular Fluid Less Than 30 Days Following Treat mentWith Intravitreal Anti-VEGF Therapy Sponsor: Vitreous-Retina-Macula Consultants of New York Purpose: To compare intravitreally administered 0.5 mg ranibizumab to 2.0 mg ranibizumab in subjects who manifest persistent or recurrent macular fluid less than 30 days following treatment with intravitreal anti-VEGF therapy Design: Interventional, Randomized, Efficacy Study, Parallel Assignment, Single-blind, Treatment Number of Patients: 30 Inclusion Criteria: Subfoveal neovascularization secondary to AMD; BCVA in the study eye between 20/30 to 20/400 using an ETDRS chart; documentation of the presence of subretinal fluid and/or cystoid macular edema on SD-OCT less than 30 days following at least six months of anti-VEGF therapy Exclusion Criteria: Prior treatment with anti-VEGF therapy in the study eye within 30 days of BSL; prior treatment with triamcinolone in the study eye within six months of BSL; prior treatment with dexamethasone in the study eye within 30 days prior to BSL Information: pguerrero@vrmny.com ► Study: A Prospective Study Comparing Ranibizumab Plus Dexamethasone Combination Therapy Versus Ranibizumab Monotherapy for Wet AMD (Lucedex) Sponsor: Bay Area Retina Associates Purpose: To evaluate the safety of intravitreal ranibizumab in combination with intravitreal dexamethasone in comparison to intravitreal ranibizumab alone in the treatment of wet AMD Design: Randomized, Safety, Parallel Assignment, Single-blind, Supportive-care Number of Patients: 40 Inclusion Criteria: All lesion subtypes will be enrolled with the following criteria: Predominantly and minimally classic: angiographic lesion greater than 50% of the total lesion area; occult: lesions must show recent activity progression with respect to vision, subretinal hemorrhage or subretinal fluid Exclusion Criteria: Previous treatment for AMD in the study eye; previous intravitreal drug delivery in the study eye; previous vitrectomy in the study eye Information: lsray01@yahoo.com ► Study: A Safety and Efficacy Study of E10030 (Anti-PDGF Pegylated Aptamer) Plus Lucentis for Neovascular Age-Related Macular Degeneration Sponsor: Ophthotech Corporation Information: (919) 456-5103 ► Study: Safety and Tolerability Study of AAV2-sFLT01 in Patients With Neovascular Age-Related Macular Degeneration (AMD) Sponsor: Genzyme Information: medinfo@genzyme.com ► Study: Study of Intravitreal Microplasmin in Relieving Vitreo-Macular Adhesion in Neovascular Age-related Macular Degeneration (AMD) Sponsor: University of California-Los Angeles/ThomboGenics Information: ostrick@jsei.ucla.edu ► Study: Retinal and Retinal Pigment Epithelium (RPE) Autoimmunity in AMD—Correlation With Lucentis Therapy (Antibody) Sponsor: University of California–Davis/Genentech Information: dgtelander@ucdavis.edu ► Study: A Phase 1 Ascending and Parallel Group Trial to Establish the Safety, Tolerability and Pharmacokinetics Profile of Volociximab (Alpha 5 Beta 1 Integrin Antagonist) in Subjects With Neovascular Age-Related Macular Degeneration Sponsor: Ophthotech Corp. Information: (212) 845-8214 ► Study: Evaluation of Dosing Interval of Higher Doses of Ranibizumab (BGB/IST) Sponsor: Retina Vitreous Associates, P.C.;Genentech Information: cawh@aol.com ► Study: The MAP Study: FA/Medidur for AMD Pilot Sponsor: Johns Hopkins Univ./Alimera Sciences Information: ghafiz1@jhmi.edu ► Study: Antioxidant Systems and AMD Sponsor: Vanderbilt University/National Institutes of Health. Information: paul.sternberg@vanderbilt.edu ► Study: High Speed Indocyanine Green Angiography Findings in Ranibizumab Treatment for Wet AMD Sponsor: National Eye Institute Information: prpl@mail.cc.nih.gov |
![]({"src":"/media/xkom03ev/102011.jpg","focalPoint":null,"crops":[{"alias":"thumbnail","width":1110,"height":700,"coordinates":null}]})